PDCD1 and neoplasm: Tumor were rapidly decreased and obtained partial remission (PR) after two cycles of Nivolumab, and the lesions present a good trend to decrease in the follow-up treatment.It was confirmed that the anti PD-1 therapy has continued to shrink the tumor.